zopiclone (Zimovane) Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Zopiclone, sold under the brand name Imovane among others, is a nonbenzodiazepine used to treat difficulty sleeping. Zopiclone is molecularly distinct from benzodiazepine drugs and is classed as a cyclopyrrolone. However, zopiclone increases the normal transmission of the neurotransmitter gamma-aminobutyric acid (GABA) in the central nervous system, via modulating GABAA receptors similarly to the way benzodiazepine drugs do.   Wikipedia

Chemistry

  • SMILES: CN1CCN(CC1)C(=O)OC2N(C(=O)c3nccnc23)c4ccc(Cl)cn4
  • InChIKey: GBBSUAFBMRNDJC-UHFFFAOYSA-N
  • Mol. Mass: 388.82
  • ALogP: 1.57
  • ChEMBL Molecule:
    zopiclone  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$0.3448 - $0.4156
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1-piperazinecarboxylic acid, 4-methyl-, 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5h-pyrrolo(3,4-b)pyrazin-5-yl ester | 6-(5-chloro-2-pyridinyl)-7-oxo-6,7-dihydro-5h-pyrrolo[3,4-b]pyrazin-5-yl 4-methyl-1-piperazinecarboxylate | 6-(5-chloro-2-pyridyl)-6,7-dihydro- 7-oxo-5h-pyrrolo(3,4-b)pyrazin-5-yl 4-methyl-1- piperazinecarboxylate | imovane | limovan | nu-zopiclone | optidorm | ratio-zopiclone | rhovane | rp 27 267 | rp-27267 | siaten | somnosan | ximovan | zileze | zileze 3.75 | zileze 7.5 | zimoclone | zimovane | zimovane ls | zop | zopicalm | zopicalma | zopiclodura | zopiclona | zopiclon abz | zopiclon al | zopiclon azu | zopiclon beta | zopiclone | (+-)-zopiclone | (+)-zopiclone | (±)-zopiclone | zopiclon-neuraxpharm | zopiclon-ratiopharm | zopiclon stada | zopiclon tad | zopiclon-teva | zopiclonum | zopiclon von ct | zopi-puren | zopitan | zorclone

Organizations (33)

Research & Development (33)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (19)

Approved Indications (1)


 

Sleep Initiation and Maintenance Disorders

Experimental Indications - Clinical Trial Phases 1-4 (19)


 

Acne Vulgaris (Phase 3)

Alcohol Drinking (Phase 1)

Anxiety (Phase 4)

Anxiety Disorders (Phase 3)

Dementia (Phase 3)

Depression (Phase 3)

Depressive Disorder, Major (Phase 1)

Healthy Volunteers (Phase 3)

Mental Disorders (Phase 1)

Parkinson Disease (Early Phase 1)

Psychophysiologic Disorders (Phase 3)

Schizophrenia (Phase 3)

Sleep (Phase 4)

Sleep Apnea, Central (Phase 4)

Sleep Apnea, Obstructive (Phase 3)

Sleep Disorders, Circadian Rhythm ()

Sleep Initiation and Maintenance Disorders (Phase 4)

Sleep Wake Disorders (Phase 4)

Ventricular Dysfunction (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 26
  • # of Trial Organizations: 33

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue